Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.60 |
| ▸ | CIT | O14578 | 14/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009459 | 0.89 | CIT (0.64) | JAK1CITAURKAAURKB | |
| SCHEMBL30009316 | 0.87 | JAK1 (0.54) | JAK1CITNEK1 | |
| SCHEMBL30009617 | 0.82 | JAK1 (0.63) | JAK1KITPDGFRACITKDR | |
| SCHEMBL30009201 | 0.81 | JAK1 (0.62) | JAK1CITNEK1AURKAAURKB | |
| SCHEMBL4794287 | 0.80 | CIT (0.66) | KITCITKDRAURKALYN | |
| SCHEMBL4794268 | 0.80 | AURKB (0.73) | CITKDRAURKALYNIGF1R | |
| SCHEMBL1718374 | 0.80 | CIT (0.71) | CIT | |
| SCHEMBL28891155 | 0.79 | KIT (0.74) | KITPDGFRAKDR | |
| SCHEMBL4791969 | 0.79 | CIT (0.63) | CITAURKAAURKB | |
| SCHEMBL30009371 | 0.79 | CIT (0.63) | CITAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885KIT 3668/4885PDGFRA 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.